SIONNA THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
SIONNA THERAPEUTICS, INC. (SION) reported Payments to Acquire Debt Securities, Available-for-sale of $58.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $33.03M, a 41.45% decline year-over-year.
- SIONNA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $25.33M, a 85.24% decline year-over-year.
- SIONNA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $42.88M, a 495.53% increase year-over-year.
- SIONNA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $54.14M, a 134.43% increase year-over-year.
- SIONNA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $325.02M, a 77.76% increase from fiscal 2024.
- SIONNA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $182.84M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $58.36M 10-Q · filed 2026-08-06 | $101.24M derived: sum of 3 quarters · filed 2026-08-06 | $155.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $25.33M 10-Q · filed 2026-05-12 | $68.20M derived: sum of 2 quarters · filed 2026-05-12 | $122.34M derived: sum of 3 quarters · filed 2026-05-12 | $178.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $42.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $97.01M derived: sum of 2 quarters · filed 2026-03-02 | $153.43M derived: sum of 3 quarters · filed 2026-08-06 | $325.02M 10-K · filed 2026-03-02 |
| 2025-09-30 | $54.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $110.55M derived: sum of 2 quarters · filed 2026-08-06 | $282.15M 10-Q · filed 2025-11-05 | $289.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $56.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $228.01M 10-Q · filed 2026-08-06 | $235.21M derived: sum of 3 quarters · filed 2026-08-06 | $258.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $171.59M 10-Q · filed 2026-05-12 | $178.79M derived: sum of 2 quarters · filed 2026-05-12 | $201.89M derived: sum of 3 quarters · filed 2026-05-12 | $230.51M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $30.29M derived: sum of 2 quarters · filed 2026-03-02 | $58.91M derived: sum of 3 quarters · filed 2026-03-02 | $182.84M 10-K · filed 2026-03-02 |
| 2024-09-30 | $23.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $51.71M derived: sum of 2 quarters · filed 2025-11-05 | $175.64M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $28.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $152.55M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $123.93M 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |